Login to Your Account



Medivir Pulls Plug on HCV NS5A; Lack of Market Demand

By Marie Powers
Staff Writer

Wednesday, August 21, 2013
With lead hepatitis C virus (HCV) candidate simeprevir (TMC435) nearing the finish line and two nucleotide (nuc) polymerase inhibitor candidates for HCV in its pipeline, Medivir AB pulled the plug on its NS5A inhibitor program, citing lack of market demand, difficulty meeting its development timetable and the desire to reallocate in-house resources.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription